Febe Smits

4PUBLICATIONS

11CO-AUTHORS

Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersGene and molecular therapy

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (4)

Sort by Publication Date:

|Jun 09, 2026

Sustained disease remission after a limited duration of bispecific antibody therapy in patients with multiple myeloma.

|Dec 10, 2025

Uncovering the ultra-frail: A distinct subgroup in non-transplant eligible newly diagnosed patients with multiple myeloma, with an inferior clinical outcome.

Kazimierz Groen, Febe Smits, Kazem Nasserinejad

|Oct 07, 2025

Immune signatures in older patients with newly diagnosed multiple myeloma are associated with survival outcomes of first-line therapy irrespective of frailty levels.

Wassilis S C Bruins, Febe Smits, Carolien Duetz

|Sep 17, 2025

The Two Sides of Bispecific Antibodies in Multiple Myeloma: Where Trial Promise Meets Real-World Practice.

Sonja Zweegman, Febe Smits, Niels W C J van de Donk

Pageof 1

Frequent Collaborators

3 joint publications

Niels W C J van de Donk

Kazimierz Groen

Sonja Zweegman

Wassilis S C Bruins

Charlotte L B M Korst

1 joint publications

A Vera de Jonge

1 joint publications

Maarten R Seefat

1 joint publications

Ghulam Rehman Mohyuddin

1 joint publications

Carolina Schinke

1 joint publications

Rajshekhar Chakraborty

Frequent Collaborators

3 joint publications

Niels W C J van de Donk

2 joint publications

Kazimierz Groen

1 joint publications

Sonja Zweegman

1 joint publications

Wassilis S C Bruins